NEWS
Our Latest News
ARCHIMED concludes successfully its £203 million take-private bid for drug development software leader Instem
ARCHIMED concludes successfully its £203 million take-private bid for drug development software leader Instem
November
27,
2023
ARCHIMED creates a leading specialized dermatological-focused CRO via the simultaneous purchase & merger of Symbio and Proinnovera
November
17,
2023
ARCHIMED top-ranked buyout fund MED I earns 4.5x on the sale of Vita
October
27,
2023
368